Kainos Medicine, Inc. (KOSDAQ: 284620)

Market Cap	94.55B
Revenue (ttm)	n/a
Net Income (ttm)	39.92M
Shares Out	28.18M
EPS (ttm)	6.18
PE Ratio	2,368.42
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,810,091
Open	3,430.00
Previous Close	3,265.00
Day's Range	2,990.00 - 3,560.00
52-Week Range	2,130.00 - 7,100.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About Kainos Medicine

Kainos Medicine, Inc. researches and develops various medicines for cancers, brain, and infectious diseases in South Korea and internationally. The company’s product pipeline includes KM-819, which is completed Phase I clinical study for the treatment of Parkinson’s disease; and KM023, a novel non-nucleoside reverse transcriptase inhibitor that is in Phase III clinical study to treat HIV/AIDS. It is also developing anticancer agents, including DNA methyltransferase inhibitor; gene target anti-cancer agent; and Ara-C, a cytotoxic anti-cancer age...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2007
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 284620